| Outcome Measures: |
Primary: Frequency of patients achieving HbA1c reduction of at least 1%-point, Week 0, week 52 | Secondary: Change in HbA1c (Glycosylated haemoglobin)), Week 0, week 104|Change in body weight, Week 0, week 104|Frequency of patients achieving HbA1c reduction of at least 1%-point, After 4 and 24 months of treatment|Frequency of patients achieving HbA1c target (<=7%), After 4, 12 and 24 months|Frequency of patients achieving a body weight reduction of at least 3%, After 4, 12 and 24 months|Frequency of patients achieving the composite endpoint consisting in: HbA1c reduction of at least 1%-point and body weight reduction of at least 3%, After 4, 12 and 24 months|Percentage of treatment discontinuation for any reason, At 4, 12 and 24 months|Changes in blood pressure and lipid profile, Week 0, week 104
|
